Iran Plans to Abandon One of Its Homegrown Covid Shots
The defense ministry said there was too little demand for its Fakhravac vaccine to justify producing it, and blamed the health ministry for reneging on promised orders.
The defense ministry said there was too little demand for its Fakhravac vaccine to justify producing it, and blamed the health ministry for reneging on promised orders.
The drug, Aduhelm, brought in $300,000 in revenue in its first full three months of availability. The company expects the drug to generate minimal revenue for the rest of the year.
Regulatory hurdles and supply chain issues could slow efforts to produce generic versions of Merck’s antiviral molnupiravir for developing nations, despite licensing agreements.
It depends.
Experts strongly agree that the shots benefit the mother as well as the fetus.
Experts strongly agree that the shots benefit the mother as well as the fetus.
The F.D.A. may authorize booster shots of vaccines different from the ones that Americans originally received. The science behind the move is promising.
The agency may act this week, when it is expected to authorize booster shots for recipients of the Moderna and Johnson & Johnson vaccines.
Merck has taken a step to make its antiviral pill available in poor nations, but many obstacles remain for broad access to coronavirus drugs.
Testimony addressed the question of whether Theranos was misleading and deceiving big corporations to get money.